Penetrium Bioscience KRX:187660KOSDAQ
현대ADM · Korean news coverage and regulatory filings, organized.
Articles, 24h15
Articles, 7 days18
DART filings, 7 days2
Articles tracked18since Sep 11
In Q2 2026, Penetrium Bioscience reported revenue of ₩2.1bn, down 16.2% year on year, and an operating loss of ₩1.9bn. Penetrium Bioscience (현대ADM) appeared in 18 Korean news articles and 2 DART filings over the past seven days. Coverage peaked on Sep 14 with 13 articles. The most common catalyst was clinical & approvals (3).
Penetrium Bioscience quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩2.1bn | -16.2% | −₩1.9bn | −₩1.5bn |
| Q1 2026 | ₩1.7bn | -23.5% | −₩1.8bn | −₩1.9bn |
| Q4 2025 derived | ₩1.9bn | -9.9% | −₩1.6bn | −₩4.5bn |
| Q3 2025 | ₩2.6bn | +27.5% | −₩1.5bn | −₩8.5bn |
| Q2 2025 | ₩2.5bn | -3.9% | −₩1.7bn | ₩1.8bn |
| Q1 2025 | ₩2.2bn | -24.6% | −₩2.7bn | −₩3.7bn |
| Q4 2024 derived | ₩2.1bn | -22.0% | −₩1.0bn | −₩2.3bn |
| Q3 2024 | ₩2.0bn | -37.2% | −₩2.6bn | −₩3.8bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Penetrium Bioscience top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest Penetrium Bioscience news Korean headlines
-
세계적 암 석학들도 페니트리움바이오서 미래 봤다… 美 2a상 ‘자발적 러브콜’
1 more on this story · 1 outlets
- 세계적 암 석학들도 페니트리움바이오서 미래 봤다… 美 2a상 ‘자발적 러브콜’이데일리 · 10:20
-
페니트리움바이오, CAF 방어막에 갇힌 항암제… 페니트리움 병용하자 암세포 ‘궤멸’
1 more on this story · 1 outlets
- 페니트리움바이오, CAF 방어막에 갇힌 항암제… 페니트리움 병용하자 암세포 ‘궤멸’이데일리 · Sep 14 14:41
